Arcus Biosciences Inc [RCUS] stock is trading at $10.50, down -3.58%. An important factor to consider is whether the stock is rising or falling in short-term value. The RCUS shares have gain 3.35% over the last week, with a monthly amount drifted -21.52%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on February 26, 2025, when H.C. Wainwright upgraded its rating to a Buy and also boosted its price target to $24 from $18. Previously, H.C. Wainwright started tracking the stock with Neutral rating on October 21, 2024, and set its price target to $20. On October 08, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $29 on the stock. BofA Securities started tracking the stock assigning a Neutral rating and suggested a price target of $33 on November 18, 2022. Morgan Stanley initiated its recommendation with a Overweight and recommended $40 as its price target on October 11, 2022. In a note dated November 24, 2020, Berenberg initiated an Buy rating and provided a target price of $50 on this stock.
Arcus Biosciences Inc [RCUS] stock has fluctuated between $9.85 and $20.00 over the past year. Currently, Wall Street analysts expect the stock to reach $32.5 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $10.50 at the most recent close of the market. An investor can expect a potential return of 209.52% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Arcus Biosciences Inc [NYSE:RCUS] reported sales of 258.00M for the trailing twelve months, which represents a drop of -16.13%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -1.28%, Pretax Profit Margin comes in at -1.1%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.47 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.18 points at the first support level, and at 9.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.96, and for the 2nd resistance point, it is at 11.42.
Ratios To Look Out For
For context, Arcus Biosciences Inc’s Current Ratio is 4.50. On the other hand, the Quick Ratio is 4.50, and the Cash Ratio is 0.66. Considering the valuation of this stock, the price to sales ratio is 4.31, the price to book ratio is 2.00.
Transactions by insiders
Recent insider trading involved KANEKO YASUNORI, Director, that happened on Feb 27 ’25 when 20000.0 shares were purchased. Chief Executive Officer, ROSEN TERRY J completed a deal on Feb 27 ’25 to buy 19800.0 shares. Meanwhile, 10% Owner GILEAD SCIENCES, INC. bought 1.36 million shares on Feb 18 ’25.
